Skip to main content
Pure Biologics S.A. logo

Pure Biologics S.A. — Investor Relations & Filings

Ticker · PUR ISIN · PLPRBLG00010 LEI · 2594002TXS19AUYHIF82 WAR Manufacturing
Open in API
Filings indexed 515 across all filing types
Latest filing 2024-08-05 Board/Management Inform…
Country PL Poland
Listing WAR PUR

About Pure Biologics S.A.

https://purebiologics.com/

Pure Biologics S.A. is a biopharmaceutical company engaged in the discovery and development of novel biological drugs and non-systemic therapies. The company leverages its expertise in antibody and aptamer technologies to create innovative treatments. Its therapeutic portfolio is primarily focused on immuno-oncology. A key aspect of its strategy is the development of original, non-generic and non-biosimilar, biological drug candidates.

Recent filings

Filing Released Lang Actions
Życiorys zawodowy nowo powołanego członka Rady Nadzorczej
Board/Management Information Classification · 98% confidence The document text is a detailed professional biography ('Życiorys zawodowy') of an individual named Mirosław Ciućman, specifically mentioning his role as a member of the Supervisory Board ('członek Rady Nadzorczej') of Pure Biologics S.A. This content directly relates to the background, qualifications, and history of a member of the company's governing body. This aligns perfectly with the 'Board/Management Information' category, which covers announcements of changes or profiles of directors and senior management.
2024-08-05 Polish
Zmiany w składzie Rady Nadzorczej Emitenta - Content (PL)
Board/Management Information Classification · 99% confidence The document text explicitly discusses the resignation of a member from the Supervisory Board ('Rada Nadzorcza') and the subsequent co-optation (appointment) of a new member, Mr. Mirosław Ciućman. This content directly relates to changes in the company's board of directors or senior management. This aligns perfectly with the definition for Board/Management Information (MANG). The document also includes details about the qualifications of the newly appointed member, which is typical for such announcements.
2024-08-05 Polish
Projety uchwał na NWZ Pure Biologics S.A.
AGM Information Classification · 98% confidence The document text consists of multiple resolutions ('Uchwała') passed by an Extraordinary General Meeting ('Nadzwyczajne Walne Zgromadzenie') of Pure Biologics S.A. on August 28, 2024. The resolutions cover procedural matters (electing a chairman, adopting the agenda) and substantive corporate actions, specifically: 1) Issuance of subscription warrants (Series C) and conditional capital increase via new shares (Series P) without pre-emptive rights, tied to an investment agreement; and 2) Adoption of the remuneration policy for management and supervisory board members. Since the document details the resolutions and decisions made during a General Meeting, it directly relates to the proceedings and outcomes of that meeting. This aligns best with the 'AGM Information' category, as an Extraordinary General Meeting (EGM) is a type of General Meeting. Although it contains elements that might touch upon Capital/Financing (CAP) and Remuneration (DEF 14A), the primary context is the formal record of the meeting itself.
2024-08-02 Polish
Ogłoszenie o zwołaniu NWZ Pure Biologics S.A.
AGM Information Classification · 99% confidence The document is titled "OGŁOSZENIE ZARZĄDU PURE BIOLOGICS S.A. Z SIEDZIBĄ WE WROCŁAWIU O ZWOŁANIU NADZWYCZAJNEGO WALNEGO ZGROMADZENIA SPÓŁKI" (Announcement of the Management Board of Pure Biologics S.A. regarding the convening of an Extraordinary General Meeting of the Company). It details the date (August 28, 2024), location, and detailed agenda (Porządek obrad) for an Extraordinary General Meeting (Nadzwyczajne Walne Zgromadzenie). It also outlines shareholder rights regarding participation, voting, submitting proposals, and appointing proxies, referencing the Polish Commercial Companies Code (KSH). This content is characteristic of a formal notice convening a shareholder meeting, which aligns directly with the definition of AGM Information (AGM-R), as it is the material announcing and detailing the meeting itself, distinct from a proxy statement (PSI) or voting results (DVA).
2024-08-02 Polish
Informacja o zwołaniu Nadzwyczajnego Walnego Zgromadzenia Pure Biologics S.A. wraz z treścią projektów uchwał - Content (PL)
AGM Information Classification · 97% confidence The document is a short regulatory filing (1149 characters) written in Polish. Key phrases include 'niniejszym informuje o zwołaniu Nadzwyczajnego Walnego Zgromadzenia Spółki' (hereby informs about the convening of an Extraordinary General Meeting of the Company) and 'w załączeniu do niniejszego raportu bieżącego, Spółka przekazuje treść projektów uchwał' (attached to this current report, the Company provides the content of draft resolutions). This indicates the document is announcing a meeting and providing related materials (draft resolutions). Since it is announcing the convening of a General Meeting and providing associated materials, it strongly relates to the AGM process. However, based on the 'MENU VS MEAL' rule, because it is a short announcement stating that materials are attached or available, it is best classified as a Report Publication Announcement (RPA) or, given the context of a General Meeting announcement, potentially AGM-R if the focus is purely on the meeting notice. Since the core action is announcing the meeting and attaching/linking the resolutions, and it is not the full presentation or the voting results, AGM-R (AGM Information) is the most specific fit for the subject matter (convening an EGM/AGM), even though it functions as an announcement. If AGM-R was not available, RPA would be considered. Given the specific mention of convening the 'Nadzwyczajnego Walnego Zgromadzenia' (Extraordinary General Meeting), AGM-R is the most appropriate classification for the subject matter being communicated.
2024-08-02 Polish
Pierwsze podanie kandydata na lek PBA-0405 u ludzi - Content (PL)
Regulatory Filings Classification · 92% confidence The document text reports on a significant clinical development milestone: the first administration of a drug candidate (PBA-0405) to a human patient in a Phase 0 study for head and neck cancer. It details the procedure, expected timelines for immunohistochemical results, and the strategic importance of this data for potential partnership. This type of announcement, detailing progress in drug development, clinical trials, or key scientific findings, is typically classified as an Investor Presentation (IP) if it were a deck, or often falls under general regulatory updates. However, given the specific nature of reporting on clinical trial progress and scientific milestones, it is most closely aligned with providing key information to investors about the pipeline. Since there is no specific code for 'Clinical Trial Update,' and it is not a formal financial report (10-K, IR), earnings release (ER), or management discussion (MDA), it functions as critical information for investors. In the absence of a dedicated 'Clinical Trial Update' code, and considering it's a detailed update on a core asset, it fits best as an Investor Presentation (IP) or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the detailed nature of the scientific update, IP is a strong candidate, but since it is framed as a formal 'raport bieżący' (current report) update, RNS (Regulatory Filings) serves as the most appropriate general regulatory disclosure category for non-standard, yet material, operational news that doesn't fit the other specific financial/governance codes. The document length is moderate (2013 chars), suggesting it is the content itself, not just an announcement of content (RPA). I will classify it as RNS as it is a material, non-financial regulatory disclosure.
2024-07-18 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.